Encaleret ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 235 | Hypoparathyroidism | 1 |
235. Hypoparathyroidism
Clinical trials : 88 / Drugs : 107 - (DrugBank : 24) / Drug target genes : 5 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05735015 (ClinicalTrials.gov) | March 22, 2023 | 17/2/2023 | Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgical Hypoparathyroidism (PSH) | Phase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects With Post-Surgical Hypoparathyroidism (PSH) | Post-Surgical Hypoparathyroidism | Drug: encaleret | National Institute of Dental and Craniofacial Research (NIDCR) | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |